Drugs / BPR-101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07483671 | Apr 2026 → Jan 2027 expected | bacterial vaginosis | Chengdu Syncor Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BPR-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07483671 ↗ |
| Route | Oral | “administered vaginally and orally as per study protocol.” NCT07483671 ↗ |